RPG Life Sciences Ltd

NSE
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

Start SIP in RPG Life Sciences Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
78.78% Gain from 52W Low
4.4
TTM PE Ratio
Below industry Median
29.6
Price to Book Ratio
High in industry
6.9
Dividend yield 1yr %
Below industry Median
0.8
TTM PEG Ratio
PEG TTM is less than 1
1
RSI
RSI is mid-range
63.2
MFI
MFI strongly Overbought
82.6

RPG Life Sciences Ltd shareholding Pattern

Promoter
72.8%
Foreign Institutions
0.9%
Mutual Funds
1.5%
Domestic Institutions
4.2%
Public
22.1%
Promoter
72.8%
Foreign Institutions
0.6%
Mutual Funds
1.1%
Domestic Institutions
3.8%
Public
22.8%
Promoter
72.8%
Foreign Institutions
0.5%
Mutual Funds
0.8%
Domestic Institutions
3.6%
Public
23.1%
Promoter
72.8%
Foreign Institutions
0.3%
Domestic Institutions
2.3%
Public
24.6%
Promoter
72.8%
Foreign Institutions
0.4%
Domestic Institutions
2.1%
Public
24.7%
Promoter
72.6%
Foreign Institutions
0.2%
Domestic Institutions
2%
Public
25.1%

RPG Life Sciences Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
1,551.60
10Day EMA
1,534.30
12Day EMA
1,528.40
20Day EMA
1,513.40
26Day EMA
1,507.90
50Day EMA
1,503.00
100Day EMA
1,488.40
200Day EMA
1,402.50
5Day SMA
1,548.00
10Day SMA
1,540.60
20Day SMA
1,492.10
30Day SMA
1,490.00
50Day SMA
1,497.40
100Day SMA
1,528.90
150Day SMA
1,488.60
200Day SMA
1,449.10
Delivery & Volume
Resistance & Support
1,563.95
Pivot
Resistance
First Resistance
1,576.90
Second Resistance
1,587.55
Third Resistance
1,600.50
Support
First Support
1,553.30
Second support
1,540.35
Third Support
1,529.70
Relative Strength Index
63.18
Money Flow Index
82.58
MACD
20.51
MACD Signal
10.24
Average True Range
48.51
Average Directional Index
18.80
Rate of Change (21)
4.81
Rate of Change (125)
15.34
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Amrutanjan Health Care Ltd.
2171.04
563.9
804
IOL Chemicals and Pharmaceuticals Ltd.
2440.97
330.85
535.9
Morepen Laboratories Ltd.
2752.13
28.6
57.83
Suven Life Sciences Ltd.
2166.34
59.6
129
Novartis India Ltd.
-
-
-
Jeena Sikho Lifecare Ltd.
-
-
-

RPG Life Sciences Ltd Company background

Founded in: 2007
Managing director: Yugal Sikri
RPG Life Sciences, formerly Searle India Ltd, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).The company is having research and development facilities that conform to international standards. It has Biotech RD, API RD and Formulations RD. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat.RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 200708, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd.During the year 200809, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, QugylO Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 200910, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, antiulcerant, antidepressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments.The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 200910. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, antiulcerant, antidepressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010.New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neolife). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 201011. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 201617. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 201617.In 201718, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the posttransplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY18. It retained leadership position in Mauritius, through antidiabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space.During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, TJAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and AldactoneF was launched in FY22.
Read More

RPG Life Sciences Ltd FAQs

RPG Life Sciences Ltd shares are currently priced at 1566.25 on NSE and 1560.75 on BSE as of 6/20/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of RPG Life Sciences Ltd [RPGLIFE] share was 67.31. The RPG Life Sciences Ltd [RPGLIFE] share hit a 1-year low of Rs. 876.1 and a 1-year high of Rs. 1740.

The market cap of RPG Life Sciences Ltd is Rs. 2590.42 Cr. as of 6/20/2024 12:00:00 AM.

The PE ratios of RPG Life Sciences Ltd is 29.45 as of 6/20/2024 12:00:00 AM.

The PB ratios of RPG Life Sciences Ltd is 6.88 as of 6/20/2024 12:00:00 AM

The Mutual Fund Shareholding was 1.47% at the end of 6/20/2024 12:00:00 AM.

You can easily buy RPG Life Sciences Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage